Periocular Gene Transfer of sFlt-1 Suppresses Ocular Neovascularization and Vascular Endothelial Growth Factor-Induced Breakdown of the Blood-Retinal Barrier

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Human Gene Therapy

• Publication date

  2003-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/104303403321070829PMID 12614564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ocular neovascularisation and excessive vascular permeability

  2004cited by this paper
• Gene therapy for proliferative ocular diseases

  2004cited by this paper
• Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis.

  2004cited by this paper
• Periocular routes for retinal drug delivery

  2004cited by this paper
• AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization.

  2002cited by this paper
• Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies.

  2002cited by this paper
• Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1

  2002cited by this paper
• Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy

  2002cited by this paper
• Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth.

  2002cited by this paper
• Quantitative assessment of the integrity of the blood-retinal barrier in mice.

  2002cited by this paper
• Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.

  2001cited by this paper
• Inhibition of Angiogenesis by Adenovirus-Mediated sFlt-1 Expression in a Rat Model of Corneal Neovascularization

  2001cited by this paper
• Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina.

  2001cited by this paper
• VEGF-initiated blood-retinal barrier breakdown in early diabetes.

  2001cited by this paper
• Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin.

  2001cited by this paper
• Systemically Expressed Soluble Tie2 Inhibits Intraocular Neovascularization

  2001cited by this paper
• Pigment epithelium‐derived factor inhibits retinal and choroidal neovascularization

  2001influential reference
• Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin.

  2001cited by this paper
• Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.

  2000cited by this paper
• Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.

  2000cited by this paper
• Quantitative image analysis of laser-induced choroidal neovascularization in rat.

  2000cited by this paper
• VEGF is major stimulator in model of choroidal neovascularization.

  2000cited by this paper
• Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.

  2000influential reference
• Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration

  2000influential reference
• Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells.

  2000cited by this paper
• Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina.

  1999cited by this paper
• Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.

  1999cited by this paper
• Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.

  1999cited by this paper
• Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha.

  1998cited by this paper
• Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates.

  1998influential reference
• Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model.

  1998cited by this paper
• Adeno-Associated Virus Gene Transfer to Mouse Retina

  1998cited by this paper
• Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.

  1998cited by this paper
• Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors.

  1998cited by this paper
• Regional Suppression of Tumor Growth by In Vivo Transfer of a cDNA Encoding a Secreted Form of the Extracellular Domain of the flt-1 Vascular Endothelial Growth Factor Receptor

  1998cited by this paper
• Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus.

  1997cited by this paper
• Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction.

  1997cited by this paper
• Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease.

  1997cited by this paper
• Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.

  1997cited by this paper
• Essential role of growth hormone in ischemia-induced retinal neovascularization.

  1997cited by this paper
• Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization.

  1997cited by this paper
• Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes

  1997cited by this paper
• A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4

  1996cited by this paper
• Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

  1996cited by this paper
• Localization of vascular endothelial growth factor in human retina and choroid.

  1996cited by this paper
• Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.

  1996cited by this paper
• Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

  1995cited by this paper
• Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.

  1995cited by this paper
• Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

  1994cited by this paper
• Oxygen-induced retinopathy in the mouse.

  1994cited by this paper
• Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa.

  1992cited by this paper
• Argon laser photocoagulation for macular edema in branch vein occlusion.

  1986cited by this paper
• Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group.

  1985cited by this paper
• Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group.

  1984cited by this paper
• Physical mapping of a large-plaque mutation of adenovirus type 2

  1979cited by this paper

• Diabetic Retinopathy in Focus: Update on Treatment Advances, Pharmaceutical Approaches, and New Technologies.

  2025cites this paper
• Gene therapy in neovascular age related macular degeneration: an update

  2025cites this paper
• Retinal Cell Damage in Diabetic Retinopathy

  2023cites this paper
• Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases.

  2023cites this paper
• Experiment-Based Interventions to Diabetic Retinopathy: Present and Advances

  2022cites this paper
• Unconventional avenues to decelerated Diabetic retinopathy.

  2022cites this paper
• Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis

  2021cites this paper
• Ocular Inflammation with Anti-Vascular Endothelial Growth Factor Treatments

  2021cites this paper
• Gene Therapy for Retinal Diseases

  2021cites this paper
• Updates on Gene Therapy for Diabetic Retinopathy

  2020influential citation
• Increased serum levels of soluble CD146 and vascular endothelial growth factor receptor 2 in patients with exudative age-related macular degeneration.

  2019cites this paper
• Novel stem cell and gene therapy in diabetic retinopathy, age related macular degeneration, and retinitis pigmentosa

  2019cites this paper
• Increased serum levels of soluble CD 146 and vascular endothelial growth factor receptor 2 in patients with exudative age-related macular degeneration

  2019cites this paper
• Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies

  2018cites this paper
• Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?

  2017cites this paper
• The Diabetic Retina: Anatomy and Pathophysiology

  2017cites this paper
• Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1

  2016cites this paper
• Risk factors and biomarkers of age-related macular degeneration.

  2016cites this paper
• Advances in Gene Therapy for Diseases of the Eye

  2016cites this paper
• Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration

  2016cites this paper
• Inhibitors of Angiogenesis.

  2016cites this paper
• Interleukin-4 and granulocyte-macrophage colony-stimulating factor mediates the upregulation of soluble vascular endothelial growth factor receptor-1 in RAW264.7 cells-a process in which p38 mitogen-activated protein kinase signaling has an important role.

  2016cites this paper
• Antiangiogenic Eye Gene Therapy

  2015cites this paper
• Development of gene therapy for treatment of age‐related macular degeneration

  2014cites this paper
• Chapter 34 – Gene Therapy for Retinal Disease

  2013cites this paper
• Microvascular complications and diabetic retinopathy: recent advances and future implications.

  2013cites this paper
• Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors.

  2013cites this paper
• Increased plasma levels of soluble vascular endothelial growth factor receptor 1 (sFlt-1) in women by moderate exercise and increased plasma levels of vascular endothelial growth factor in overweight/obese women

  2013cites this paper
• Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization

  2013cites this paper
• Pharmacotherapy of Age-Related Macular Degeneration

  2012cites this paper
• Viral Transgene Expression Delivered by Repeat Intraocular Adenoviral Vector Injection: in Vivo Live Imaging Study

  2012cites this paper
• Gene therapy in age related macular degeneration and hereditary macular disorders.

  2012cites this paper
• Soluble VEGFR1 (sVEGFR1) as a novel marker of amyotrophic lateral sclerosis (ALS) in the North Indian ALS patients

  2012influential citation
• Gene transfer for ocular neovascularization and macular edema

  2011cites this paper
• Signaling Mechanism of Blood-Retinal Barrier Regulation: Role of Mitogen-Activated

  2011cites this paper
• Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability.

  2011cites this paper
• Microvascular Modifications in Diabetic Retinopathy

  2011cites this paper
• Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates

  2011cites this paper
• Adeno-Associated Vector (Type 8)-Mediated Expression of Soluble Flt-1 Efficiently Inhibits Neovascularization in a Murine Choroidal Neovascularization Model

  2010cites this paper
• Inhibition of Choroidal Neovascularization via Brief Subretinal Exposure to a Newly Developed Lentiviral Vector Pseudotyped with Sendai Viral Envelope Proteins

  2010cites this paper
• EUROPEAN SCHOOL OF MOLECULAR MEDICINE

  2010cites this paper
• Effect of intensive insulin therapy on macular biometrics, plasma VEGF and its soluble receptor in newly diagnosed diabetic patients

  2010cites this paper
• Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt.

  2010cites this paper
• Pathophysiology of Diabetic Retinopathy

  2010cites this paper
• Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization

  2009cites this paper
• A Compartment Model of VEGF Distribution in Humans in the Presence of Soluble VEGF Receptor-1 Acting as a Ligand Trap

  2009cites this paper
• Equine Infectious Anemia Viral Vector-Mediated Codelivery of Endostatin and Angiostatin Driven by Retinal Pigmented Epithelium-Specific VMD2 Promoter Inhibits Choroidal Neovascularization

  2009cites this paper
• A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use

  2009cites this paper
• rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector.

  2009cites this paper
• Ocular gene therapy: current progress and future prospects.

  2009cites this paper
• Vascular Endothelial Growth Factors In Eye Diseases Pathophysiology and New Therapeutic Strategies for Retinal and Choroideal Angiogenesis

  2009cites this paper
• Modification of adenovirus capsid proteins for gene therapy applications

  2009cites this paper
• HIV-1-mediated delivery of a short hairpin RNA targeting vascular endothelial growth factor in human retinal pigment epithelium cells

  2009cites this paper
• Pigment Epithelium-Derived Factor and Angiogenesis

  2008cites this paper
• Trans-scleral Delivery of Antiangiogenic Proteins

  2008cites this paper
• Vascular endothelial growth factor and diabetic complications.

  2008cites this paper
• Long-term genetic modification of the ocular outflow tract and the retinal pigment epithelium with feline immunodeficiency viral vectors

  2008cites this paper
• Repeat administration of proteins to the eye with a single intraocular injection of an adenovirus vector.

  2008cites this paper
• Effects of bevacizumab (Avastin) on retinal cells in organotypic culture.

  2008cites this paper
• Alternate serotype adenovector provides long-term therapeutic gene expression in the eye

  2008cites this paper
• Helper‐dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy

  2007cites this paper
• Gene therapy for ocular neovascularization.

  2007cites this paper
• Molecular targets for retinal vascular diseases

  2007cites this paper
• Protein Transport to Choroid and Retina following Periocular Injection: Theoretical and Experimental Study

  2007cites this paper
• Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice

  2007cites this paper
• Seeing the light: New insights into the molecular pathogenesis of retinal diseases

  2007cites this paper
• Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD.

  2006cites this paper
• Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier

  2006cites this paper
• Plasmid expression vector encoding sFLT-1 receptor (psFLT-1) inhibits angiogenesis and L1 tumour growth

  2006cites this paper
• Repeated administration of adenovector in the eye results in efficient gene delivery.

  2006cites this paper
• Vascular Endothelial Growth Factor and Retinal Diseases

  2006cites this paper
• Delivery from episcleral exoplants.

  2006cites this paper
• Recombinant non‐collagenous domain of α2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis

  2006cites this paper
• Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.

  2006cites this paper
• Inhibitors of ocular neovascularization: promises and potential problems.

  2005cites this paper
• Nonviral ocular gene transfer

  2005cites this paper
• Periocular Gene Transfer of Pigment Epithelium-Derived Factor Inhibits Choroidal Neovascularization in a Human-Sized Eye

  2005cites this paper
• A system for inducible gene expression in retinal ganglion cells.

  2005cites this paper
• Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity.

  2005cites this paper
• Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice.

  2005cites this paper
• Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys.

  2005cites this paper
• Therapeutic applications of vascular endothelial growth factor

  2005cites this paper
• Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis

  2004cites this paper
• Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis.

  2004cites this paper
• Ocular neovascularisation and excessive vascular permeability

  2004cites this paper
• Periocular routes for retinal drug delivery

  2004influential citation
• Marked inhibition of retinal neovascularization in rats following soluble‐flt‐1 gene transfer

  2004cites this paper
• Gene therapy for proliferative ocular diseases

  2004cites this paper
• Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization.

  2004cites this paper
• Ocular neovascularization: a valuable model system

  2003cites this paper
• A Vascular Endothelial Growth Factor High Affinity Receptor 1-specific Peptide with Antiangiogenic Activity Identified Using a Phage Display Peptide Library*

  2003cites this paper
• Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model.

  2003cites this paper